Eatontown, NJ, July, 25 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Bupropion HCl immediate-release 75 and 100mg tablets. This launch adds to Avet’s robust portfolio of generic oral solid products. Bupropion is the AB rated generic equivalent to the antidepressant drug Wellbutrin®. It is indicated for the treatment of depression. According to IMS data for the twelve-months ended May 2017, the U.S. market for Bupropion immediate-release tablets is approximately $42.6 million.